Phage therapy in a lung transplant recipient with cystic fibrosis infected with multidrug‐resistant Burkholderia multivorans
Transplant Infectious Disease · 2023-04 · 25 (2)
DOI: 10.1111/tid.14041 ↗Kurz gefasst
Fallbericht in der Zeitschrift Transplant Infectious Disease, online erschienen am 02.03.2023. Verfasst von Ghady Haidar und 15 weiteren Autor:innen. Beteiligte Einrichtung: Division of Infectious Diseases, University of Pittsburgh School of Medicine, Pittsburgh, Pennsylvania, USA. Hauptthemen laut MEDLINE: Cystic Fibrosis, Burkholderia cepacia complex, Burkholderia Infections, Phage Therapy. Die Arbeit wurde bisher 40-mal zitiert (Crossref) und nennt 21 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY-NC-ND 4.0). Gefördert von: NIAID NIH HHS, Cystic Fibrosis Foundation, National Institute of Allergy and Infectious Diseases.
Abstract (Originalsprache)
Background
There is increased interest in bacteriophage (phage) therapy to treat infections caused by antibiotic‐resistant bacteria. A lung transplant recipient with cystic fibrosis and Burkholderia multivorans infection was treated with inhaled phage therapy for 7 days before she died.
Methods
Phages were given via nebulization through the mechanical ventilation circuit. Remnant respiratory specimens and serum were collected. We quantified phage and bacterial deoxyribonucleic acid (DNA) using quantitative polymerase chain reaction, and tested phage neutralization in the presence of patient serum. We performed whole genome sequencing and antibiotic and phage susceptibility testing on 15 B. multivorans isolates. Finally, we extracted lipopolysaccharide (LPS) from two isolates and visualized their LPS using gel electrophoresis.
Results
Phage therapy was temporally followed by a temporary improvement in leukocytosis and hemodynamics, followed by worsening leukocytosis on day 5, deterioration on day 7, and death on day 8. We detected phage DNA in respiratory samples after 6 days of nebulized phage therapy. Bacterial DNA in respiratory samples decreased over time, and no serum neutralization was detected. Isolates collected between 2001 and 2020 were closely related but differed in their antibiotic and phage susceptibility profiles. Early isolates were not susceptible to the phage used for therapy, while later isolates, including two isolates collected during phage therapy, were susceptible. Susceptibility to the phage used for therapy was correlated with differences in O‐antigen profiles of an early versus a late isolate.
Conclusions
This case of clinical failure of nebulized phage therapy highlights the limitations, unknowns, and challenges of phage therapy for resistant infections. image
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Division of Infectious Diseases, University of Pittsburgh School of Medicine, Pittsburgh, Pennsylvania, USA.
- Department of Ecology and Evolutionary Biology, and Yale Center for Phage Biology and Therapy, Yale University, New Haven, Connecticut, USA.
- Investigational Drug Service, University of Pittsburgh Medical Center, Pittsburgh, Pennsylvania, USA.
- Division of Pulmonary, Allergy, and Critical Care Medicine, University of Pittsburgh School of Medicine, Pittsburgh, Pennsylvania, USA.
- Department of Pediatrics, University of Michigan School of Medicine, Ann Arbor, Michigan, USA.
- Department of Microbiology and Molecular Genetics, University of Pittsburgh School of Medicine, Pittsburgh, Pennsylvania, USA.
ORCID-Profile: Ghady Haidar, Shu-Ting Cho, Kailey Hughes Kramer, Madison E Stellfox, Mische Holland, Joseph M Pilewski, John J LiPuma, Vaughn S Cooper, Ryan K Shields, Daria Van Tyne
Förderung
- NIAID NIH HHS
- Cystic Fibrosis Foundation
- National Institute of Allergy and Infectious Diseases
- Department of Medicine at the University of Pittsburgh School of Medicine
Zitieren
APA
Haidar, G., Chan, B. K., Cho, S. T., Hughes Kramer, K., Nordstrom, H. R., Wallace, N. R., Stellfox, M. E., Holland, M., Kline, E. G., Kozar, J. M., Kilaru, S. D., Pilewski, J. M., LiPuma, J. J., Cooper, V. S., Shields, R. K., & Van Tyne, D. (2023). Phage therapy in a lung transplant recipient with cystic fibrosis infected with multidrug‐resistant Burkholderia multivorans. Transplant Infectious Disease, 25(2). https://doi.org/10.1111/tid.14041
Vancouver
Haidar G, Chan BK, Cho ST, Hughes Kramer K, Nordstrom HR, Wallace NR, et al. Phage therapy in a lung transplant recipient with cystic fibrosis infected with multidrug‐resistant Burkholderia multivorans. Transplant Infectious Disease. 2023;25(2). doi:10.1111/tid.14041
BibTeX
@article{Haidar2023,
author = {Haidar, Ghady and Chan, Benjamin K and Cho, Shu-Ting and Hughes Kramer, Kailey and Nordstrom, Hayley R and Wallace, Nathan R and Stellfox, Madison E and Holland, Mische and Kline, Ellen G and Kozar, Jennifer M and Kilaru, Silpa D and Pilewski, Joseph M and LiPuma, John J and Cooper, Vaughn S and Shields, Ryan K and Van Tyne, Daria},
title = {Phage therapy in a lung transplant recipient with cystic fibrosis infected with multidrug‐resistant Burkholderia multivorans},
journal = {Transplant Infectious Disease},
year = {2023},
volume = {25},
number = {2},
doi = {10.1111/tid.14041}
}
EUVIMED